T1	Participants 116 153	sentinel lymph node-positive patients
T2	Participants 446 526	patients with sentinel lymph node-positive (SLN+) primary invasive breast cancer
T3	Participants 884 917	patients with SLN+ breast cancer.
T4	Participants 939 979	Patients with SLN+ primary breast cancer
T5	Participants 1287 1304	474 SLN+ patients
